Abstract: Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progressionfree survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.
Introduction
Ovarian cancer is the eighth-leading cause of death from cancer in women worldwide. 1 This is in large part due to a lack of effective screening mechanisms leading to predominately advanced disease at diagnosis. 2 This also contributes to a worse prognosis. 3 Although patients often have a good response to taxane and platinum-based chemotherapy, most will unfortunately relapse. 4 Recurrent ovarian cancer remains a clinical challenge, owing to its relentless trajectory to eventual drug resistance. In the setting of recurrent disease, the outcome of patients is associated with different factors including volume of disease, response to platinum-based chemotherapy, histology, performance status and genotype, such as BRCA mutation status. 2 Targeted therapies, such as antiangiogenic agents (e.g. bevacizumab and cediranib) have proven useful in extending progression-free survival (PFS), and in one instance, overall survival, for patients in the setting of recurrent disease, although no biomarkers have been prospectively validated to identify individuals that will best respond to such treatment. 3, 5, 6 While biomarkers do exist for the identification of patients most likely to respond to poly (ADPribose) polymerase (PARP) inhibitors (discussed below), this phenotype is somatically dynamic, eventually leading to drug resistance 7 and highlighting the unmet medical need for new treatment approaches and strategies.
Role of homologous recombination deficiency and PARP inhibitors in ovarian cancer
In epithelial ovarian cancer, homologous recombination (HR) is an important pathway that allows repair of double-stranded DNA breaks. Data from the Cancer Genome Atlas (TCGA) estimate that approximately 50% of high-grade serous ovarian cancers have genomic alterations that could impair homologous recombination response (HRR). 8 Both germline and de novo somatic mutations in HRR genes can result in ovarian cancer. BRCA germline mutations in the United States (US) population occur in about 15% of women with high-grade epithelial ovarian cancer; de novo somatic BRCA mutations are found in another 5-7% in several cohorts of patients; [9] [10] [11] however, the true prevalence remains unknown. In some population clusters, more than 24% of ovarian cancers are associated with BRCA germline mutations. 12 Initially, the majority of homologous recombination deficiency (HRD) tumors were discovered in patients with germline BRCA1 and BRCA2 mutations. 13 Further studies showed that, in addition to these genes, there are many others involved in HR DNA repair, a phenotype called BRCA-like. The most common are the Fanconi anemia pathway genes (RAD51C, RAD51D, RAD50, BRIP1, BARD1, CHEK2, MRE11A, NBN, PALB2) and the mismatch repair genes (MLH1, MSH2, MSH6, PMS2). 14, 15 Epithelial ovarian cancers with HRD have increased sensitivity to PARP inhibitors. 16 The PARP enzymes are involved in DNA repair through activation of the base excision repair. The 17-member PARP superfamily of nuclear enzymes includes PARP1, PARP2, and PARP3, which are activated by DNA damage. 17 There are many proposed mechanisms through which inhibition of PARP leads to cancer cell death; 18 however, a commonly referred to mechanism is the sequential inhibition of DNA single strand breaks that ultimately accumulate into DNA double-strand breaks (DSB), which in the absence of competent HRR leads to catastrophic cell damage. This process is frequently regarded as synthetic lethality. 19 Another DNA repair pathway is DSB recombination repair, which includes the nonhomologous end-joining (NHEJ). 20 It is also recognized that trapped PARP and DNA complexes can cause PARP inactivation. 21, 22 Rucaparib (formerly known as CO-338, AG-14699, and PF-01367338) is a potent PARP1, PARP2 and PARP3 inhibitor, and to a lesser extent PARP4, PARP10, PARP12, PARP15, and PARP16 and a mild inhibitor of PARP5a and PARP5b. 23 In 2011, in vitro studies have shown that rucaparib exhibits off-target effects with respect to PARP1 and PARP2. 22 Subsequently, preclinical studies revealed that tumors with mutated or epigenetically silenced BRCA1/2 were sensitive to rucaparib. 24 Between 2013 and 2016, three clinical trials: Study 10 (a phase I/II treatment trial), 25 ARIEL 2 (a phase II treatment trial), and ARIEL 3 (a phase III switch maintenance trial), 26, 27 have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma.
Pharmacokinetics and pharmacodynamics of rucaparib
Rucaparib can be taken with or without food but has different pharmacokinetic parameters when taken with food (versus fasting) probably due to solubility in the small intestine. The mean fasting half-life is 17 h and the median time to maximal concentration is 1.9 h and can be delayed by 2.5 h after a high fat meal; however, the moderate food effect on pharmacokinetics was not considered to be clinically significant. The cytochrome P450 enzymatic pathway is responsible for rucaparib metabolism (primarily CYP2D6 and to a lesser extent by CYP1A2, and CYP3A4). 28, 29 Dosing toxicity and pharmacokinetic assessments documented in the phase I part of the Study 10 concluded that rucaparib 600 mg twice daily was safe and manageable, and was the recommended dose for future studies. 25 
Clinical efficacy of rucaparib in ovarian cancer
Treatment Study 10 was a phase I-II trial that evaluated rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. The phase II part enrolled 42 patients with platinum-sensitive, high-grade, predominately serous ovarian carcinoma associated with a germline BRCA1/2 mutation who received two to four prior regimens and had a progression-free interval of 6 months or more following their most recent platinum therapy. The larger proportion of patients had a BRCA1 mutation (71.4%), and BRCA2 mutation was seen in 28.6% of patients. The investigator-assessed objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) was 59.5% and the median duration of response was 7.8 months [95% confidence interval (CI), 5.6-10.5]. 25 ARIEL 2, a two-part phase II trial 26 was conducted to assess the safety and efficacy of rucaparib in patients with platinum-sensitive, high-grade ovarian cancer patients with one or more chemotherapy regimen (part 1) or three or Table 1 . 31 The genomic molecular signature established in part 1 will be prospectively applied to part 2. Completed part 2 data are not yet available.
In a review of the safety and efficacy of rucaparib, the US Food and Drug Administration (FDA) approved rucaparib to treat women with advanced ARIEL 3 trial validated the next generation sequence HRD assay used in the previous trial. An additional exploratory endpoint was done to assess outcomes in women whose tumors had mutations in non-BRCA HRR genes. Overall, deleterious mutations were detected in 43/564 (7.6%) patients. In the rucaparib group with a non-BRCA HRD gene mutation (n = 28), the most common gene mutations were RAD51C (n = 6), RAD51D (n = 4), and RAD54L (n = 3 beyond those with germline BRCA mutations that may benefit from treatment with a PARP inhibitor. 34 Deficiency in HR DNA repair leads to loss or duplication of chromosomal regions. Next generation sequencing assays can quantify this genomic instability by measuring the percentage of genome-wide allelic imbalance or LOH, as a surrogate marker for HRD. 35, 36 In the phase II and III trials of rucaparib in epithelial ovarian cancer, the HRD signature was chosen based on an association between the extent of LOH in tumor's samples and the clinical benefit from rucaparib treatment. 26, 27 Tumor was evaluated for HRR mutation and LOH using the Foundation Medicine T5 next generation sequence assay (Cambridge). One of the main advantages of detecting tumor genomic LOH is that it can identify HRD-positive tumors regardless of the underlying mechanisms, which include both known (i.e. BRCA mutations) and unknown genetic and other mechanisms. 23 In the ARIEL2 part 1 trial [ClinicalTrials.gov identifier: NCT01891344], the prespecified cutoff to define LOH high was of 14% or higher. 26 Review of these data enabled optimization of the degree of LOH associated with clinical efficacy and were prospectively defined in ARIEL 3 [ClinicalTrials.gov identifier: NCT01968213] as ⩾16%. 27 However, even in the ITT population of ARIEL 3, a benefit with rucaparib in PFS was seen. The limitation of using a genomic scars it that past signatures may be present and confound the interpretation of clinical results if the tumor became resistant. 37 Other measures of HRD have been evaluated in prospective trials, including that assessed in the phase III switch maintenance trial of niraparib in women with platinum-sensitive recurrent ovarian cancer response to induction platinum combination therapy (NOVA trial, ClinicalTrials.gov identifier: NCT01847274). 38 In that study, HRD was defined using a composite of factors associated with genomic instability, including LOH, telomeric allelic imbalance and large-scale state transitions (Myriad MyChoice, Salt Lake City, UT, USA). 38 Of note, in the NOVA trial, patients with nongermline BRCA mutation were randomized in a cohort that included HRD (defined as somatic BRCA mutation and nongermline BRCA mutation-associated HRD) and non-HRD genomic assessment. In this study niraparib demonstrated significant improvement over placebo among patients with HRD as assessed by this test.
However, a lesser but statistically significant benefit was seen in the HRD-negative cohort suggesting that these biomarkers may not be sufficiently precise to predict absence of benefit on an individual basis. 38 The optimal method for the identification of which BRCA wildtype cancers are most likely to respond to a PARP inhibitor is still unknown. However, efforts to validate an HRD tool as a predictive biomarker with high sensitivity and specificity is a highly desired goal for future studies. Given the dynamic alterations that occur in the tumor microenvironment in response to intrinsic and extrinsic stress, 39 real-time surveillance tools are likely to be necessary to help clinicians in directing treatment decisions.
Safety and tolerability of rucaparib
Several different PARP inhibitors have been approved in the last few years and although longterm follow up is required for a precise assessment of safety, rucaparib appears to have a manageable toxicity profile. In the phase II part of Study 10, the most common treatment-emergent adverse events (AEs) of grades 3 or 4 were anemia (38.1%), asthenia/fatigue (26.2%) and alanine aminotransferase or aspartate transferase elevations (14.3%). The grade 3 or 4 AEs were managed with treatment modification or supportive care. In the phase 2 ARIEL2 trial, rucaparib displayed a satisfactory safety profile and toxicity similar to Study 10. 26 All patients had at least one treatment-emergent AE and the most frequent grade 3 or greater AEs were anemia or decreased hemoglobin in 22% of patients and elevations in alanine aminotransferase or aspartate aminotransferase in 12% of patients. An integrated analysis of the antitumor activity and safety of Study 10 and ARIEL2 trials revealed that rucaparib has a manageable safety profile. 40 No new safety signals appeared in the much larger ARIEL 3 trial. 27 Aligned with previous experience and noted as probable class effects, the most common AEs were: nausea (75%), asthenia/fatigue (69%), constipation (37%) and vomiting (37%). Grade 3 or 4 AEs were seen in 56% of patients in the rucaparib group. AEs leading to dose reduction were observed in 55% and 4% of patients in the rucaparib and placebo group, respectively. Treatment interruption due to a treatment-emergent AE was common and occurred in 64% of patients in the rucaparib group and 10% in the placebo group. However, treatment discontinuation due to a treatment-emergent AE was far lower (13%) and compared with 2% in the placebo group. The most common serious AEs were anemia (4% of patients), pyrexia (2%), vomiting (2%) and small intestinal obstruction (1%).
Considering laboratory abnormalities, decreased hemoglobin concentration (anemia) was the most common AE, occurring in any grade in 37% of patients and in 19% grade 3 or greater. A decline in hemoglobin concentration occurred generally in the first few cycles. Compared with other PARP inhibitors, anemia is a common side effect for this class of drug and it was noticed as grade 3 or greater in 19% of patient using olaparib 41 and in 25.3% of patients using niraparib. 38 Another AE noticed in ARIEL 3 that was seen less frequently with other PARP inhibitors was an increase in alanine aminotransferase or aspartate aminotransferase concentration (grade 3-4: 34% of rucaparib-treated patients versus 10% with placebo). These transaminase alterations were transient, self-limiting, and not associated with any parameters of hepatic dysfunction. Grade 1 or 2 creatinine increases were observed within the first few weeks of rucaparib treatment and then stabilized with continued rucaparib treatment.
Rucaparib and others PARP inhibitors
Others PARP inhibitors have also been approved for the treatment of ovarian cancer. Olaparib was the first PARP inhibitor approved by the US FDA. In the US, olaparib was first approved as monotherapy with the capsule formulation for patients with high-grade ovarian carcinoma and germline BRCA1 or 2 mutation who have received three or more prior chemotherapies on 19 December 2014. 16 The SOLO-2 trial was a phase III study that evaluated olaparib as a maintenance treatment of patients with high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with platinum-sensitive, relapsed, BRCA-mutated who had received at least two lines of previous chemotherapy and had an objective response to platinum-based chemotherapy. In this study, the investigator-assessed median PFS was significantly longer in the olaparib arm Veliparib is a PARP inhibitor that is not approved but has been evaluated in a phase II trial for the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation. The ORR in platinum-resistant and platinum-sensitive patients was 20% and 35%, respectively. 42 An ongoing placebo-controlled phase III trial in newly diagnosed ovarian cancer patients, which is combining veliparib/placebo and chemotherapy, followed by veliparib/ placebo maintenance has recently completed enrolment [ClinicalTrials.gov identifier: NCT 02470585].
Currently, there are no head-to-head trials of PARP inhibitors in the setting of high-grade recurrent platinum-sensitive ovarian cancer. However, it is important to recognize that despite the fairly homogeneous outcomes across these three phase III trials, several design, population, and assessment differences exist. These are summarized in Table 2 .
There are still many unanswered questions regarding the use of PARP inhibitors in ovarian cancer, such as the optimal timing and duration of administration of these drugs, the long-term effects of PARP inhibition, how PARP inhibitor resistance develops, whether PARP inhibitors can be used again if previously administered, whether there are combinations that can overcome HR resistance (innate or induced), whether PARP inhibitor response can be augmented in cohorts where they are already known to be clinically active, and how somatic events can be evaluated and addressed in 'real-time'. The answers to these questions will have a profound impact on the broader clinical utility of this class of agent in journals.sagepub.com/home/tam 7 patients with solid tumors. A summary of the results of single-agent trials of PARP inhibitors in ovarian cancer is presented in Table 3 .
Future directions and conclusions
To further investigate the activity of rucaparib, additional studies have been designed with the aim to assess the role of rucaparib in different clinical settings. The ARIEL4 is an ongoing phase III trial that will compare the efficacy and safety of rucaparib with chemotherapy (monotherapy platinum or platinum doublet; investigator's choice: carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine) as a treatment for relapsed ovarian, fallopian tube, or primary peritoneal cancer with BRCA germline or somatic mutations who have received two or more prior lines of chemotherapy. The physician's choice option allows for platinum-based chemotherapy. The primary outcome is PFS and secondary outcomes are overall survival, safety and tolerability of rucaparib as compared with chemotherapy [ClinicalTrials. gov identifier: NCT02855944]. 49 The results of ARIEL 3 and ARIEL 4 will help to further understand the ideal timing of use of rucaparib, as a maintenance or treatment for patients with relapsed disease. Another trial that is expected to begin soon is the ATHENA study, a first-line maintenance treatment trial with four arms (rucaparib in combination with nivolumab, rucaparib, nivolumab and placebo) in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube or primary peritoneal cancer who have completed platinum-based chemotherapy. 50 Rucaparib has also been evaluated as monotherapy in other solid tumors in different ongoing tri Table 4 shows the ongoing clinical trials of rucaparib in monotherapy in different solid tumors. Rucaparib and temozolomide were studied in a phase II trial for patients with melanoma, where 36 % of patients were progression-free at 6 months. 51 The CheckMate 9KD [ClinicalTrials.gov identifier: NCT03338790] will evaluate the combination of nivolumab and rucaparib in mCRPC. A trial is 23, 52 In summary, the use of rucaparib showed an increase in PFS compared with placebo in all patients with ovarian carcinoma who achieved response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug in the third-line of platinum-sensitive disease, as also with the companion diagnostic test, represents an important new therapeutic option in the treatment of ovarian cancer. Based on these findings, a new drug application of rucaparib is under review by the US FDA, as a maintenance treatment for women with platinum-sensitive recurrent ovarian cancer following response to induction platinum-based therapy (Prescription Drug User Fee Act date: 6 April 2018). Further evaluation of rucaparib in other disease cohorts and in combination with other agents is warranted. Intensive efforts in the characterization of tumor biomarkers are ongoing, and a systematic approach will likely be necessary to better identify the patients that will better respond to therapy. 
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